Traws Pharma Inc. (TRAW) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
Capital intensity & 0% operating margin leave 16 pts on the table
While TRAW currently carries a cautious 38/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.49) and Max Pain ($0.32) forces dealer call-delta covering toward $3.39.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Traws Pharma Inc. (TRAW) dropped -16.34% to $0.30, trading at 2% of its 52-week range ($0.29 – $3.23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Traws Pharma, Inc.Up to 135,135,135 Shares of Common StockThis prospectus relates to the resale by Roth Principal Investments, LLC, a Delaware limited liability company ("Roth Principal Investments" or the
SGRY led gap-ups at 46.25% and XP led gap-downs at -50.48% in today's session, with SPRC, RENT, XNCR, XXII, DAICW and AGBK among notable gap movers.
-SEC Filing
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TRAW today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TRAW. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Traws Pharma Inc. (TRAW) ranks #733 by composite RQD confidence (38/100, grade D-) and #953 by equity capitalization ($4.6M). Within this direct 5-issuer industry benchmark cohort, TRAW leads on earnings valuation at N/A trailing P/E, while TRAW leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NCNA currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with TRAW at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TRAW
ACTIVE
Traws Pharma Inc. | D- | 38/100 | — | — | -35.0% | -16.34% | $4.6M | Benchmark Subject |
| AZTR Azitra Inc | D- | 41/100 | — | — | -35.0% | -16.31% | $4.6M | /aztr-vs-traw → |
| IMNN Imunon Inc. | D- | 42/100 | — | — | -35.0% | +0.35% | $4.7M | /imnn-vs-traw → |
| NCNA NuCana plc | D+ | 56/100 | — | — | — | -3.26% | $4.3M | /ncna-vs-traw → |
| XTLB XTL Biopharmaceuticals Ltd. | D | 47/100 | — | — | — | -12.44% | $4.3M | /xtlb-vs-traw → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Traws Pharma Inc. (TRAW) reported GAAP revenue of $2.8M (+1134.5% vs. FY2024 revenue of $226.0K , and +1134.5% cumulative change since FY2023) , GAAP net income of $9.2M, operating cash flow of -$18.2M, and free cash flow of -$18.2M (+39.0% YoY). On the balance sheet, TRAW closed FY2025 with $10.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.8M | $9.2M | -$18.2M | -$18.2M | $10.6M | — |
| FY2024 (FY) | 2024-12-31 | $226.0K | -$166.5M | -$29.8M | -$29.8M | $25.0M | — |
| FY2023 (FY) | 2023-12-31 | $226.0K | -$18.9M | -$17.9M | -$17.9M | — | — |
As of 2026-11-01, Traws Pharma Inc. (NASDAQ: TRAW) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.30 (-16.34% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TRAW ranks #733 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRAW carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AZTR (Azitra Inc) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $4.6M) and IMNN (Imunon Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, TRAW leads on earnings multiple (N/A) while TRAW leads on capital efficiency (-35.0% ROIC).
Per TRAW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130598), Traws Pharma Inc. generated $2.8M in revenue (+1134.5% YoY), $9.2M in net income, and -$18.2M in free cash flow against $10.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
TRAW last traded at $0.30 (-16.34% on volume of 718,988 shares), positioning the stock -38.78% below its 50-day simple moving average ($0.49) and -74.36% below its 200-day simple moving average ($1.17). Across its 52-week range of $0.29 to $3.23, TRAW sits at the 0.3% percentile with a 14-day RSI of 25.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.34).
Why TRAW Stock dropped -16.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.